Enfortumab vedotin for advanced penile cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a drug called enfortumab vedotin for people with advanced penile cancer (squamous cell carcinoma) that has spread or cannot be surgically removed. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have squamous cell carcinoma of the penis that has spread or cannot be removed with surgery.
- You must have at least one tumor that can be measured on scans.
- You need to be in good enough health to be up and about (ECOG score 0 or 1).
- Your blood counts (red blood cells, white blood cells, platelets) and liver/kidney function must be within certain limits.
- You cannot have other serious health issues like uncontrolled diabetes, recent heart problems, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (enfortumab vedotin and avelumab) as a first treatment for men with advanced or metastatic penile cancer that cannot be removed by surgery. The goal is to see if this new combination can shrink tumors and improve outcomes.
This trial tests a drug called enfortumab vedotin for people with advanced small bowel adenocarcinoma that has worsened after platinum-based chemotherapy. The goal is to see if it can shrink tumors or slow the disease.
This trial tests a new combination treatment for advanced penile cancer that hasn't been treated before. It combines a targeted drug (becotatug vedotin) designed to attack cancer cells with an immunotherapy drug (pucotenlimab) that helps your immune system fight cancer.
This study tests a new drug called enfortumab vedotin for people whose advanced urothelial cancer (bladder or urinary tract cancer) has not responded to prior immunotherapy (checkpoint inhibitors) and platinum chemotherapy. The goal is to see how safe and effective this treatment is for Indian adults.
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
This trial tests a drug called enfortumab vedotin for people whose colorectal or liver cancer has spread or cannot be removed and has stopped responding to or is intolerant to standard treatments. The drug is given through a vein and works by targeting cancer cells.
Hear when a new Metastatic Penile Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.